NovelCath
Manufacturing · Minnesota, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
8609 Xylon Ct Ste 101A, Minneapolis, Min...Phone Number
(763) 494-5551Website
www.novelcath.comRevenue
$125.6 MillionIndustry
About NovelCath
NovelCath is a contract manufacturer based in Minneapolis, MN, specializing in the design, development, and manufacturing of minimally invasive interventional delivery systems for applications in Structural Heart, Electrophysiology, and Neurovascular fields. The company, part of Cirtec Medical, integrates Cardea Catheter Innovations to enhance its capabilities in producing complex catheter devices. With a team of industry veterans boasting over 70 years of experience, NovelCath focuses on R&D and prototyping to support early-stage development programs. Their vertically integrated facility includes advanced technologies for catheter assembly and Nitinol processing.Explore more
SIC Code 38,382NAICS Code 33,339Show moreNovelCath Org Chart
Compare Similar Companies to NovelCath
Compare insights from companies similar to NovelCath, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
NovelCath
$125.6M
501-1,000
Private
<$5M
1973
TJ
Terrell JacobsSenior General Manager, Catheter Technologies
NovelCath Tech Stack
A closer look at the technologies used by NovelCath
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NovelCath
Sign Up For FreeTo access detailed company insights
NovelCath is a contract manufacturer based in Minneapolis, MN, specializing in the design, development, and manufacturing of minimally invasive interventional delivery systems for applications in Structural Heart, Electrophysiology, and Neurovascular fields. The company, part of Cirtec Medical, integrates Cardea Catheter Innovations to enhance its... Read More